ArticleLab on a chip2023
Red blood cell rosetting enables size-based separation of specific lymphocyte subsets from blood in a microfluidic device.
Article in Lab on a chip, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- An integrated automated deep learning framework for annotating tumor-infiltrating lymphocytes in lung adenocarcinoma pathology.Frontiers in bioinformatics · 2026Article
- Robust and efficient separation of white blood cells from blood using a microfluidic chip with a pair of linearly tapered crossflow filter arrays.Mikrochimica acta · 2024Article
- Characterization of the phagocytic ability of white blood cells separated using a single curvature spiral microfluidic device.Biomedical engineering letters · 2024Article
- A Review of Research Progress in Microfluidic Bioseparation and Bioassay.Micromachines · 2024Review
- Separation of platelets by size in a microfluidic device based on controlled incremental filtration.Lab on a chip · 2024Article
- Rapid, label-free enrichment of lymphocytes in a closed system using a flow-through microfluidic device.Bioengineering & translational medicine · 2024Article
- Blood component separation in straight microfluidic channels.Biomicrofluidics · 2023Article
- Acoustophoretic Characterization and Separation of Blood Cells in Acoustic Impedance Gradients.Physical review applied · 2023Article
- Manufacturing regulatory T cells for adoptive cell therapy in immune diseases: A critical appraisal.Clinical immunology (Orlando, Fla.) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The isolation of a specific lymphocyte subset from blood is the required first step in the manufacturing of many novel cellular immunotherapies. Microfluidic size-based separation methods are poised to significantly simplify this process because they require neither centrifugation nor magnetic or fluorescent labeling to operate. Lymphocytes can be separated from red blood cells (RBCs) and platelets as well as monocytes and granulocytes because their size differs from each of these cell types. However, further separation of a specific lymphocyte subset from other unwanted lymphocytes using size-based methods is impossible because all lymphocytes have approximately the same size and can only be distinguished by surface markers. This paper describes a new approach that made it possible for a size-based separation method to isolate a desired subset of lymphocytes by making unwanted lymphocytes as well as other blood cells artificially larger. The separation was enabled by selectively binding multiple RBCs to each unwanted cell to create 'rosettes' with an effective size significantly larger than the diameter of a typical lymphocyte. The desired lymphocytes remained unaffected by rosetting and were separated from the rosettes by passing the mixture through a microfluidic size-based separation device based on controlled incremental filtration (CIF). This new rosette-enabled size-based (RESIZE) separation approach demonstrated recovery of 80-90% for all lymphocyte subsets tested (CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.